Skip to main content
Top
Published in: Heart and Vessels 2/2017

01-02-2017 | Original Article

Soluble TNF-related apoptosis induced ligand (sTRAIL) is augmented by Post-Conditioning and correlates to infarct size and left ventricle dysfunction in STEMI patients: a substudy from a randomized clinical trial

Authors: André Luz, Mário Santos, Rui Magalhães, José Carlos Oliveira, Ana Pacheco, João Silveira, Sofia Cabral, Severo Torres, Adelino F. Leite-Moreira, Henrique Carvalho

Published in: Heart and Vessels | Issue 2/2017

Login to get access

Abstract

Low levels of Soluble TNF-related apoptosis induced ligand (sTRAIL) seem to be related to worse prognosis after an acute coronary syndrome. PostConditioning (PostCond) may protect the heart from reperfusion injury. We sought to evaluate the impact of PostCond on sTRAIL in relationship to infarct size (area under the curve of Troponin T, AUCTnT) and left ventricle ejection fraction (LVEF) in a series of patients undergoing primary coronary intervention for ST-segment elevation myocardial infarction (STEMI). In a substudy of a randomized trial that tested the effects of PostCond in STEMI-patients, sTRAIL was measured 24 h after reperfusion (PostCond n = 39, Control n = 39). Correlations between sTRAIL and both AUCTnT and LVEF were studied for each study arm. At 24 h, sTRAIL was higher for PostCond vs Controls (46.4 ± 30.6 vs 32.9 ± 23.4, p = 0.031), was negatively related to AUCTnT [B = −0.09, 95 % CI (−0.15 to −0.30), p = 0.005] and was positively related to both in-hospital [B = 0.10, 95 % CI (0.02–0.17), p = 0.018], and follow-up LVEF [B = 0.21, 95 % (0.10–0.32), p = 0.001]. No significant relationship was found for Controls. On multivariate analysis, PostCond was an independent predictor for sTRAIL [B = 12.13 95 % CI (0.40–23.87), p = 0.043]. In conclusion, PostCond positively influenced sTRAIL, which was related to reduced infarct size and better LVEF. Further studies are needed to understand potential mechanisms elicited by PostCond in infarct size reduction.
Literature
1.
go back to reference Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van ‘t Hof A, Widimsky P, Zahger D (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619CrossRefPubMed Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van ‘t Hof A, Widimsky P, Zahger D (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619CrossRefPubMed
2.
go back to reference Pedersen F, Butrymovich V, Kelbæk H, Wachtell K, Helqvist S, Kastrup J, Holmvang L, Clemmensen P, Engstrøm T, Grande P, Saunamäki K, Jørgensen E (2014) Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol 64:2101–2108CrossRefPubMed Pedersen F, Butrymovich V, Kelbæk H, Wachtell K, Helqvist S, Kastrup J, Holmvang L, Clemmensen P, Engstrøm T, Grande P, Saunamäki K, Jørgensen E (2014) Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol 64:2101–2108CrossRefPubMed
3.
go back to reference Miyachi H, Takagi A, Miyauchi K, Yamasaki M, Tanaka H, Yoshikawa M, Saji M, Suzuki M, Yamamoto T, Shimizu W, Nagao K, Takayama M (2016) Current characteristics and management of ST elevation and non-ST elevation myocardial infarction in the Tokyo metropolitan area: from the Tokyo CCU network registered cohort. Heart Vessels. doi:10.1007/s00380-015-0791-9 PubMedPubMedCentral Miyachi H, Takagi A, Miyauchi K, Yamasaki M, Tanaka H, Yoshikawa M, Saji M, Suzuki M, Yamamoto T, Shimizu W, Nagao K, Takayama M (2016) Current characteristics and management of ST elevation and non-ST elevation myocardial infarction in the Tokyo metropolitan area: from the Tokyo CCU network registered cohort. Heart Vessels. doi:10.​1007/​s00380-015-0791-9 PubMedPubMedCentral
4.
go back to reference Prasad A, Stone GW, Holmes DR, Gersh B (2009) Reperfusion injury, microvascular dysfunction, and cardioprotection: the “dark side” of reperfusion. Circulation 120:2105–2112CrossRefPubMed Prasad A, Stone GW, Holmes DR, Gersh B (2009) Reperfusion injury, microvascular dysfunction, and cardioprotection: the “dark side” of reperfusion. Circulation 120:2105–2112CrossRefPubMed
6.
7.
go back to reference Jennings RB (2013) Historical perspective on the pathology of myocardial ischemia/reperfusion injury. Circ Res 113:428–438CrossRefPubMed Jennings RB (2013) Historical perspective on the pathology of myocardial ischemia/reperfusion injury. Circ Res 113:428–438CrossRefPubMed
8.
go back to reference Kloner RA (2013) Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circ Res 113:451–463CrossRefPubMed Kloner RA (2013) Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circ Res 113:451–463CrossRefPubMed
9.
go back to reference Ndrepepa G (2015) Improving myocardial injury, infarct size, and myocardial salvage in the era of primary PCI for STEMI. Coron Artery Dis 26:341–355CrossRefPubMed Ndrepepa G (2015) Improving myocardial injury, infarct size, and myocardial salvage in the era of primary PCI for STEMI. Coron Artery Dis 26:341–355CrossRefPubMed
10.
go back to reference Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285:H579–H588CrossRefPubMed Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285:H579–H588CrossRefPubMed
11.
go back to reference Khan AR, Binabdulhak AA, Alastal Y, Khan S, Faricy-Beredo BM, Luni FK, Lee WM, Khuder S, Tinkel J (2014) Cardioprotective role of ischemic postconditioning in acute myocardial infarction: a systematic review and meta-analysis. Am Heart J 168(512–521):e514 Khan AR, Binabdulhak AA, Alastal Y, Khan S, Faricy-Beredo BM, Luni FK, Lee WM, Khuder S, Tinkel J (2014) Cardioprotective role of ischemic postconditioning in acute myocardial infarction: a systematic review and meta-analysis. Am Heart J 168(512–521):e514
12.
go back to reference Favaretto E, Roffi M, Frigo AC, Lee MS, Marra MP, Napodano M, Tarantini G (2014) Meta-analysis of randomized trials of postconditioning in ST-elevation myocardial infarction. Am J Cardiol 114:946–952CrossRefPubMed Favaretto E, Roffi M, Frigo AC, Lee MS, Marra MP, Napodano M, Tarantini G (2014) Meta-analysis of randomized trials of postconditioning in ST-elevation myocardial infarction. Am J Cardiol 114:946–952CrossRefPubMed
13.
go back to reference Limalanathan S, Andersen GO, Klow NE, Abdelnoor M, Hoffmann P, Eritsland J (2014) Effect of ischemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI results of the POSTEMI (POstconditioning in ST-Elevation Myocardial Infarction) randomized trial. J Am Heart Assoc 3:e000679CrossRefPubMedPubMedCentral Limalanathan S, Andersen GO, Klow NE, Abdelnoor M, Hoffmann P, Eritsland J (2014) Effect of ischemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI results of the POSTEMI (POstconditioning in ST-Elevation Myocardial Infarction) randomized trial. J Am Heart Assoc 3:e000679CrossRefPubMedPubMedCentral
14.
go back to reference Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, Lips DJ, Doevendans PA (2004) Role of apoptosis in reperfusion injury. Cardiovasc Res 61:414–426CrossRefPubMed Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, Lips DJ, Doevendans PA (2004) Role of apoptosis in reperfusion injury. Cardiovasc Res 61:414–426CrossRefPubMed
15.
go back to reference Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL (1994) Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94:1621–1628CrossRefPubMedPubMedCentral Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL (1994) Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94:1621–1628CrossRefPubMedPubMedCentral
16.
go back to reference Badalzadeh R, Mokhtari B, Yavari R (2015) Contribution of apoptosis in myocardial reperfusion injury and loss of cardioprotection in diabetes mellitus. J Physiol Sci 65:201–215CrossRefPubMed Badalzadeh R, Mokhtari B, Yavari R (2015) Contribution of apoptosis in myocardial reperfusion injury and loss of cardioprotection in diabetes mellitus. J Physiol Sci 65:201–215CrossRefPubMed
17.
go back to reference Freude B, Masters TN, Robicsek F, Fokin A, Kostin S, Zimmermann R, Ullmann C, Lorenz-Meyer S, Schaper J (2000) Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol 32:197–208 Freude B, Masters TN, Robicsek F, Fokin A, Kostin S, Zimmermann R, Ullmann C, Lorenz-Meyer S, Schaper J (2000) Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol 32:197–208
18.
go back to reference Sasaki T, Shishido T, Kadowaki S, Kitahara T, Suzuki S, Katoh S, Funayama A, Netsu S, Watanabe T, Goto K, Takeishi Y, Kubota I (2014) Diacylglycerol kinase alpha exacerbates cardiac injury after ischemia/reperfusion. Heart Vessels 29:110–118CrossRefPubMed Sasaki T, Shishido T, Kadowaki S, Kitahara T, Suzuki S, Katoh S, Funayama A, Netsu S, Watanabe T, Goto K, Takeishi Y, Kubota I (2014) Diacylglycerol kinase alpha exacerbates cardiac injury after ischemia/reperfusion. Heart Vessels 29:110–118CrossRefPubMed
19.
go back to reference McCully JD, Wakiyama H, Hsieh YJ, Jones M, Levitsky S (2004) Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 286:H1923–H1935CrossRefPubMed McCully JD, Wakiyama H, Hsieh YJ, Jones M, Levitsky S (2004) Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 286:H1923–H1935CrossRefPubMed
20.
go back to reference Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki L-M (1997) Apoptosis in human acute myocardial infarction. Circulation 95:320–323CrossRefPubMed Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki L-M (1997) Apoptosis in human acute myocardial infarction. Circulation 95:320–323CrossRefPubMed
21.
go back to reference Biondi-Zoccai GG, Abbate A, Vasaturo F, Scarpa S, Santini D, Leone AM, Parisi Q, De Giorgio F, Bussani R, Silvestri F, Baldi F, Biasucci LM, Baldi A (2004) Increased apoptosis in remote non-infarcted myocardium in multivessel coronary disease. Int J Cardiol 94:105–110CrossRefPubMed Biondi-Zoccai GG, Abbate A, Vasaturo F, Scarpa S, Santini D, Leone AM, Parisi Q, De Giorgio F, Bussani R, Silvestri F, Baldi F, Biasucci LM, Baldi A (2004) Increased apoptosis in remote non-infarcted myocardium in multivessel coronary disease. Int J Cardiol 94:105–110CrossRefPubMed
22.
go back to reference Chen Z, Chua CC, Ho YS, Hamdy RC, Chua BH (2001) Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol Heart Circ Physiol 280:H2313–H2320PubMed Chen Z, Chua CC, Ho YS, Hamdy RC, Chua BH (2001) Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol Heart Circ Physiol 280:H2313–H2320PubMed
23.
go back to reference Rong F, Peng Z, Ye MX, Zhang QY, Zhao Y, Zhang SM, Guo HT, Hui B, Wang YM, Liang C, Gu CH, Tao C, Cui Q, Yu SQ, Yi DH, Pei JM (2009) Myocardial apoptosis and infarction after ischemia/reperfusion are attenuated by kappa-opioid receptor agonist. Arch Med Res 40:227–234CrossRefPubMed Rong F, Peng Z, Ye MX, Zhang QY, Zhao Y, Zhang SM, Guo HT, Hui B, Wang YM, Liang C, Gu CH, Tao C, Cui Q, Yu SQ, Yi DH, Pei JM (2009) Myocardial apoptosis and infarction after ischemia/reperfusion are attenuated by kappa-opioid receptor agonist. Arch Med Res 40:227–234CrossRefPubMed
24.
go back to reference Lee P, Sata M, Lefer DJ, Factor SM, Walsh K, Kitsis RN (2003) Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo. Am J Physiol Heart Circ Physiol 284:H456–H463CrossRefPubMed Lee P, Sata M, Lefer DJ, Factor SM, Walsh K, Kitsis RN (2003) Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo. Am J Physiol Heart Circ Physiol 284:H456–H463CrossRefPubMed
25.
go back to reference Senturk T, Cavun S, Avci B, Yermezler A, Serdar Z, Savci V (2014) Effective inhibition of cardiomyocyte apoptosis through the combination of trimetazidine and N-acetylcysteine in a rat model of myocardial ischemia and reperfusion injury. Atherosclerosis 237:760–766CrossRefPubMed Senturk T, Cavun S, Avci B, Yermezler A, Serdar Z, Savci V (2014) Effective inhibition of cardiomyocyte apoptosis through the combination of trimetazidine and N-acetylcysteine in a rat model of myocardial ischemia and reperfusion injury. Atherosclerosis 237:760–766CrossRefPubMed
26.
go back to reference Nilsson L, Szymanowski A, Swahn E, Jonasson L (2013) Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS One 8:e55477CrossRefPubMedPubMedCentral Nilsson L, Szymanowski A, Swahn E, Jonasson L (2013) Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS One 8:e55477CrossRefPubMedPubMedCentral
27.
go back to reference Gan R, Hu G, Zhao Y, Li H, Jin Z, Ren H, Dong S, Zhong X, Li H, Yang B, Xu C, Lu F, Zhang W (2012) Post-conditioning protecting rat cardiomyocytes from apoptosis via attenuating calcium-sensing receptor-induced endo(sarco)plasmic reticulum stress. Mol Cell Biochem 361:123–134CrossRefPubMed Gan R, Hu G, Zhao Y, Li H, Jin Z, Ren H, Dong S, Zhong X, Li H, Yang B, Xu C, Lu F, Zhang W (2012) Post-conditioning protecting rat cardiomyocytes from apoptosis via attenuating calcium-sensing receptor-induced endo(sarco)plasmic reticulum stress. Mol Cell Biochem 361:123–134CrossRefPubMed
28.
go back to reference Wagner C, Tillack D, Simonis G, Strasser RH, Weinbrenner C (2010) Ischemic post-conditioning reduces infarct size of the in vivo rat heart: role of PI3-K, mTOR, GSK-3beta, and apoptosis. Mol Cell Biochem 339:135–147CrossRefPubMed Wagner C, Tillack D, Simonis G, Strasser RH, Weinbrenner C (2010) Ischemic post-conditioning reduces infarct size of the in vivo rat heart: role of PI3-K, mTOR, GSK-3beta, and apoptosis. Mol Cell Biochem 339:135–147CrossRefPubMed
29.
go back to reference Ren Y, Cai Y, Jia D (2012) Comparative antiapoptotic effects of KB-R7943 and ischemic postconditioning during myocardial ischemia reperfusion. Cell Biochem Biophys 64:137–145CrossRefPubMed Ren Y, Cai Y, Jia D (2012) Comparative antiapoptotic effects of KB-R7943 and ischemic postconditioning during myocardial ischemia reperfusion. Cell Biochem Biophys 64:137–145CrossRefPubMed
30.
go back to reference Zhao WS, Xu L, Wang LF, Zhang L, Zhang ZY, Liu Y, Liu XL, Yang XC, Cui L, Zhang L (2009) A 60-s postconditioning protocol by percutaneous coronary intervention inhibits myocardial apoptosis in patients with acute myocardial infarction. Apoptosis 14:1204–1211CrossRefPubMed Zhao WS, Xu L, Wang LF, Zhang L, Zhang ZY, Liu Y, Liu XL, Yang XC, Cui L, Zhang L (2009) A 60-s postconditioning protocol by percutaneous coronary intervention inhibits myocardial apoptosis in patients with acute myocardial infarction. Apoptosis 14:1204–1211CrossRefPubMed
31.
go back to reference Kimberley FC, Screaton GR (2004) Following a TRAIL: update on a ligand and its five receptors. Cell Res 14:359–372CrossRefPubMed Kimberley FC, Screaton GR (2004) Following a TRAIL: update on a ligand and its five receptors. Cell Res 14:359–372CrossRefPubMed
32.
go back to reference Secchiero P, Corallini F, Ceconi C, Parrinello G, Volpato S, Ferrari R, Zauli G (2009) Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS One 4:e4442CrossRefPubMedPubMedCentral Secchiero P, Corallini F, Ceconi C, Parrinello G, Volpato S, Ferrari R, Zauli G (2009) Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS One 4:e4442CrossRefPubMedPubMedCentral
33.
go back to reference Osmancik P, Teringova E, Tousek P, Paulu P, Widimsky P (2013) Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients. PLoS One 8:e53860CrossRefPubMedPubMedCentral Osmancik P, Teringova E, Tousek P, Paulu P, Widimsky P (2013) Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients. PLoS One 8:e53860CrossRefPubMedPubMedCentral
34.
go back to reference Luz A, Santos M, Magalhaes R, Silveira J, Cabral S, Dias V, Oliveira F, Pereira S, Leite-Moreira A, Carvalho H, Torres S (2015) Lack of benefit of ischemic PostConditioning after routine thrombus aspiration during reperfusion: immediate and midterm results. J Cardiovasc Pharmacol Ther 20:523–531CrossRefPubMed Luz A, Santos M, Magalhaes R, Silveira J, Cabral S, Dias V, Oliveira F, Pereira S, Leite-Moreira A, Carvalho H, Torres S (2015) Lack of benefit of ischemic PostConditioning after routine thrombus aspiration during reperfusion: immediate and midterm results. J Cardiovasc Pharmacol Ther 20:523–531CrossRefPubMed
35.
go back to reference Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E (2000) TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infracting myocardium early II trial substudy. Circulation 102:2031–2037CrossRefPubMed Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E (2000) TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infracting myocardium early II trial substudy. Circulation 102:2031–2037CrossRefPubMed
36.
go back to reference Brandt PW, Partridge JB, Wattie WJ (1977) Coronary arteriography; method of presentation of the arteriogram report and a scoring system. Clin Radiol 28:361–365CrossRefPubMed Brandt PW, Partridge JB, Wattie WJ (1977) Coronary arteriography; method of presentation of the arteriogram report and a scoring system. Clin Radiol 28:361–365CrossRefPubMed
37.
go back to reference Graham MM, Faris PD, Ghali WA, Galbraith PD, Norris CM, Badry JT, Mitchell LB, Curtis MJ, Knudtson ML (2001) Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. Am Heart J 142:254–261CrossRefPubMed Graham MM, Faris PD, Ghali WA, Galbraith PD, Norris CM, Badry JT, Mitchell LB, Curtis MJ, Knudtson ML (2001) Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. Am Heart J 142:254–261CrossRefPubMed
38.
go back to reference Ortiz-Perez JT, Meyers SN, Lee DC, Kansal P, Klocke FJ, Holly TA, Davidson CJ, Bonow RO, Wu E (2007) Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. Eur Heart J 28:1750–1758CrossRefPubMed Ortiz-Perez JT, Meyers SN, Lee DC, Kansal P, Klocke FJ, Holly TA, Davidson CJ, Bonow RO, Wu E (2007) Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. Eur Heart J 28:1750–1758CrossRefPubMed
39.
go back to reference Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW (2005) The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1:219–227PubMed Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW (2005) The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1:219–227PubMed
40.
41.
go back to reference Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, Fabris B, Giacca M, Zauli G (2006) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114:1522–1530CrossRefPubMed Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, Fabris B, Giacca M, Zauli G (2006) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114:1522–1530CrossRefPubMed
42.
go back to reference Liu M, Xiang G, Lu J, Xiang L, Dong J, Mei W (2014) TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling. Atherosclerosis 237:718–724CrossRefPubMed Liu M, Xiang G, Lu J, Xiang L, Dong J, Mei W (2014) TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling. Atherosclerosis 237:718–724CrossRefPubMed
43.
go back to reference Toffoli B, Bernardi S, Candido R, Zacchigna S, Fabris B, Secchiero P (2012) TRAIL shows potential cardioprotective activity. Invest New Drugs 30:1257–1260CrossRefPubMed Toffoli B, Bernardi S, Candido R, Zacchigna S, Fabris B, Secchiero P (2012) TRAIL shows potential cardioprotective activity. Invest New Drugs 30:1257–1260CrossRefPubMed
44.
go back to reference Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR (2008) TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem 283:7754–7762CrossRefPubMed Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR (2008) TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem 283:7754–7762CrossRefPubMed
45.
go back to reference Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V, Forti G, Capitani S, Zauli G (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965–1974CrossRefPubMed Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V, Forti G, Capitani S, Zauli G (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965–1974CrossRefPubMed
46.
go back to reference Richter B, Koller L, Hohensinner PJ, Zorn G, Brekalo M, Berger R, Mortl D, Maurer G, Pacher R, Huber K, Wojta J, Hulsmann M, Niessner A (2013) A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol 168:1251–1257CrossRefPubMed Richter B, Koller L, Hohensinner PJ, Zorn G, Brekalo M, Berger R, Mortl D, Maurer G, Pacher R, Huber K, Wojta J, Hulsmann M, Niessner A (2013) A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol 168:1251–1257CrossRefPubMed
47.
go back to reference Volpato S, Ferrucci L, Secchiero P, Corallini F, Zuliani G, Fellin R, Guralnik JM, Bandinelli S, Zauli G (2011) Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 215:452–458CrossRefPubMed Volpato S, Ferrucci L, Secchiero P, Corallini F, Zuliani G, Fellin R, Guralnik JM, Bandinelli S, Zauli G (2011) Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 215:452–458CrossRefPubMed
48.
go back to reference Mori K, Ikari Y, Jono S, Shioi A, Ishimura E, Emoto M, Inaba M, Hara K, Nishizawa Y (2010) Association of serum TRAIL level with coronary artery disease. Thromb Res 125:322–325CrossRefPubMed Mori K, Ikari Y, Jono S, Shioi A, Ishimura E, Emoto M, Inaba M, Hara K, Nishizawa Y (2010) Association of serum TRAIL level with coronary artery disease. Thromb Res 125:322–325CrossRefPubMed
49.
go back to reference Deftereos S, Giannopoulos G, Panagopoulou V, Raisakis K, Kossyvakis C, Kaoukis A, Tzalamouras V, Mavri M, Pyrgakis V, Cleman MW, Stefanadis C (2012) Inverse association of coronary soluble tumor necrosis factor-related apoptosis inducing ligand (sTRAIL) levels to in-stent neointimal hyperplasia. Cardiology 123:97–102CrossRefPubMed Deftereos S, Giannopoulos G, Panagopoulou V, Raisakis K, Kossyvakis C, Kaoukis A, Tzalamouras V, Mavri M, Pyrgakis V, Cleman MW, Stefanadis C (2012) Inverse association of coronary soluble tumor necrosis factor-related apoptosis inducing ligand (sTRAIL) levels to in-stent neointimal hyperplasia. Cardiology 123:97–102CrossRefPubMed
50.
go back to reference Deftereos S, Giannopoulos G, Kossyvakis C, Kaoukis A, Raisakis K, Panagopoulou V, Miliou A, Theodorakis A, Driva M, Pyrgakis V, Stefanadis C, Cleman MW (2012) Association of soluble tumour necrosis factor-related apoptosis-inducing ligand levels with coronary plaque burden and composition. Heart 98:214–218CrossRefPubMed Deftereos S, Giannopoulos G, Kossyvakis C, Kaoukis A, Raisakis K, Panagopoulou V, Miliou A, Theodorakis A, Driva M, Pyrgakis V, Stefanadis C, Cleman MW (2012) Association of soluble tumour necrosis factor-related apoptosis-inducing ligand levels with coronary plaque burden and composition. Heart 98:214–218CrossRefPubMed
51.
go back to reference Secchiero P, Gonelli A, Corallini F, Ceconi C, Ferrari R, Zauli G (2010) Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis 211:333–336CrossRefPubMed Secchiero P, Gonelli A, Corallini F, Ceconi C, Ferrari R, Zauli G (2010) Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis 211:333–336CrossRefPubMed
52.
go back to reference Nakajima H, Yanase N, Oshima K, Sasame A, Hara T, Fukazawa S, Takata R, Hata K, Mukai K, Yamashina A, Mizuguchi J (2003) Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction. Jpn Heart J 44:833–844CrossRefPubMed Nakajima H, Yanase N, Oshima K, Sasame A, Hara T, Fukazawa S, Takata R, Hata K, Mukai K, Yamashina A, Mizuguchi J (2003) Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction. Jpn Heart J 44:833–844CrossRefPubMed
53.
go back to reference Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P (2003) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 92:732–740CrossRefPubMed Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P (2003) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 92:732–740CrossRefPubMed
54.
go back to reference Cheng W, Zhao Y, Wang S, Jiang F (2014) Tumor necrosis factor-related apoptosis-inducing ligand in vascular inflammation and atherosclerosis: a protector or culprit? Vascul Pharmacol 63:135–144CrossRefPubMed Cheng W, Zhao Y, Wang S, Jiang F (2014) Tumor necrosis factor-related apoptosis-inducing ligand in vascular inflammation and atherosclerosis: a protector or culprit? Vascul Pharmacol 63:135–144CrossRefPubMed
55.
go back to reference Forde H, Harper E, Davenport C, Rochfort KD, Wallace R, Murphy RP, Smith D, Cummins PM (2016) The beneficial pleiotropic effects of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) within the vasculature: a review of the evidence. Atherosclerosis 247:87–96CrossRefPubMed Forde H, Harper E, Davenport C, Rochfort KD, Wallace R, Murphy RP, Smith D, Cummins PM (2016) The beneficial pleiotropic effects of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) within the vasculature: a review of the evidence. Atherosclerosis 247:87–96CrossRefPubMed
56.
go back to reference Luz A, Santos M, Rodrigues P, Sousa MJ, Anjo D, Silveira I, Brochado B, Silveira J, Cabral S, Leite-Moreira A, Carvalho H, Torres S (2015) Preinfarction angina: clinical significance and relationship with total ischemic time in patients with ST-elevation myocardial infarction. Coron Artery Dis 26:22–29CrossRefPubMed Luz A, Santos M, Rodrigues P, Sousa MJ, Anjo D, Silveira I, Brochado B, Silveira J, Cabral S, Leite-Moreira A, Carvalho H, Torres S (2015) Preinfarction angina: clinical significance and relationship with total ischemic time in patients with ST-elevation myocardial infarction. Coron Artery Dis 26:22–29CrossRefPubMed
57.
go back to reference Hausenloy DJ, Yellon DM (2007) Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 116:173–191CrossRefPubMed Hausenloy DJ, Yellon DM (2007) Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 116:173–191CrossRefPubMed
58.
go back to reference Wang L, Li X, Zhou Y, Shi H, Xu C, He H, Wang S, Xiong X, Zhang Y, Du Z, Zhang R, Lu Y, Yang B, Shan H (2014) Downregulation of miR-133 via MAPK/ERK signaling pathway involved in nicotine-induced cardiomyocyte apoptosis. Naunyn Schmiedebergs Arch Pharmacol 387:197–206CrossRefPubMed Wang L, Li X, Zhou Y, Shi H, Xu C, He H, Wang S, Xiong X, Zhang Y, Du Z, Zhang R, Lu Y, Yang B, Shan H (2014) Downregulation of miR-133 via MAPK/ERK signaling pathway involved in nicotine-induced cardiomyocyte apoptosis. Naunyn Schmiedebergs Arch Pharmacol 387:197–206CrossRefPubMed
Metadata
Title
Soluble TNF-related apoptosis induced ligand (sTRAIL) is augmented by Post-Conditioning and correlates to infarct size and left ventricle dysfunction in STEMI patients: a substudy from a randomized clinical trial
Authors
André Luz
Mário Santos
Rui Magalhães
José Carlos Oliveira
Ana Pacheco
João Silveira
Sofia Cabral
Severo Torres
Adelino F. Leite-Moreira
Henrique Carvalho
Publication date
01-02-2017
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 2/2017
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-016-0851-9

Other articles of this Issue 2/2017

Heart and Vessels 2/2017 Go to the issue